tiprankstipranks
Advertisement
Advertisement

ARWR Stock Latest News

Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
RatingsMaintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
3h ago
ARWR
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
PremiumThe Fly
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
21h ago
WVE
ARWR
Arrowhead price target lowered to $81 from $84 at BofA
PremiumThe Fly
Arrowhead price target lowered to $81 from $84 at BofA
21h ago
ARWR
IONS
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
PremiumCompany Announcements
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
7d ago
8K
ARWR
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
PremiumCompany Announcements
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
7d ago
ARWR
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
PremiumCompany AnnouncementsArrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
2M ago
ARWR
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
Premium
The Fly
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
2M ago
ARWR
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
Premium
Ratings
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
2M ago
ARWR
Arrowhead to replace Ciena in S&P 400 at open on 2/9
PremiumThe Fly
Arrowhead to replace Ciena in S&P 400 at open on 2/9
2M ago
ARWR
CIEN
ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9
PremiumThe Fly
ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9
2M ago
ADT
ARWR
Is ARWR a Buy, Before Earnings?
PremiumPre-Earnings
Is ARWR a Buy, Before Earnings?
2M ago
ARWR
Arrowhead doses first patient in ARO-DIMER-PA trial
PremiumThe Fly
Arrowhead doses first patient in ARO-DIMER-PA trial
2M ago
ARWR
Arrowhead price target raised to $101 from $61 at B. Riley
PremiumThe FlyArrowhead price target raised to $101 from $61 at B. Riley
2M ago
ARWR
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
Premium
The Fly
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
2M ago
ARWR
Arrowhead price target raised to $110 from $100 at Piper Sandler
Premium
The Fly
Arrowhead price target raised to $110 from $100 at Piper Sandler
2M ago
ARWR
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
PremiumCompany Announcements
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
2M ago
8K
ARWR
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
PremiumCompany Announcements
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
3M ago
ARWR
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
PremiumCompany Announcements
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
3M ago
8K
ARWR
Arrowhead 3.1M share Secondary priced at $64.50
PremiumThe Fly
Arrowhead 3.1M share Secondary priced at $64.50
3M ago
ARWR
Arrowhead announces China NMPA approval for Redemplo
PremiumThe FlyArrowhead announces China NMPA approval for Redemplo
3M ago
ARWR
Arrowhead price target raised to $85 from $50 at Goldman Sachs
Premium
The Fly
Arrowhead price target raised to $85 from $50 at Goldman Sachs
3M ago
ARWR
Arrowhead price target raised to $81 from $48 at Morgan Stanley
Premium
The Fly
Arrowhead price target raised to $81 from $48 at Morgan Stanley
3M ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >